Association between dietary phyto-oestrogens and bone density in men and postmenopausal women by Kuhnle, Gunter G. C. et al.
Association between dietary phyto-oestrogens and bone density in men
and postmenopausal women
Gunter G. C. Kuhnle1,2,3*, Heather A. Ward2, Anna Vogiatzoglou1, Robert N. Luben2, Angela Mulligan2,
Nicholas J. Wareham3, Nita G. Forouhi3 and Kay-Tee Khaw2
1Department of Food and Nutritional Sciences, University of Reading, Whiteknights, PO Box 226, Reading RG6 6AP, UK
2Strangeways Research Laboratory, Department of Public Health and Primary Care, Institute of Public Health, MRC Centre
for Nutritional Epidemiology in Cancer Prevention and Survival (CNC), University of Cambridge, Wort’s Causeway,
Cambridge CB1 8RN, UK
3MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK
(Received 20 September 2010 – Revised 8 February 2011 – Accepted 9 February 2011)
Abstract
Phyto-oestrogens have been associated with a decreased risk for osteoporosis, but results from intervention and observational studies in
Western countries have been inconsistent. In the present study, we investigated the association between habitual phyto-oestrogen intake
and broadband ultrasound attenuation (BUA) of the calcanaeum as a marker of bone density. We collected 7 d records of diet, medical
history and demographic and anthropometric data from participants (aged 45–75 years) in the European Prospective Investigation into
Cancer-Norfolk study. Phyto-oestrogen (biochanin A, daidzein, formononetin; genistein, glycitein; matairesinol; secoisolariciresinol; enter-
olactone; equol) intake was determined using a newly developed food composition database. Bone density was assessed using BUA of the
calcanaeum. Associations between bone density and phyto-oestrogen intake were investigated in 2580 postmenopausal women who were
not on hormone replacement therapy and 4973 men. Median intake of total phyto-oestrogens was 876 (interquartile range 412)mg/d in
postmenopausal women and 1212 (interquartile range 604)mg/d in men. The non-soya isoflavones formononetin and biochanin A
were marginally significant or significantly associated with BUA in postmenopausal women (b ¼ 1·2; P,0·1) and men (b ¼ 1·2;
P,0·05), respectively; enterolignans and equol were positively associated with bone density in postmenopausal women, but this associ-
ation became non-significant when dietary Ca was added to the model. In the lowest quintile of Ca intake, soya isoflavones were positively
associated with bone density in postmenopausal women (b ¼ 1·4; P,0·1). The present results therefore suggest that non-soya isoflavones
are associated with bone density independent of Ca, whereas the association with soya or soya isoflavones is affected by dietary Ca.
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Dietary phyto-oestrogens have been associated with a
decreased risk for osteoporosis because of their structural
and functional similarities with 17b-oestradiol and their ability
to interact with oestrogen receptors(1,2), in particular oestro-
gen receptor-b(3). In vitro and animal studies have shown
that phyto-oestrogens can modulate bone turnover and
delay bone loss in acute oestrogen deficiency(4). However, a
meta-analysis of ten randomised clinical trials lasting at least
1 year found only a weak beneficial effect for larger doses
of isoflavones (.80 mg/d), but none for lower doses(5).
Observational studies have reported a positive association
between phyto-oestrogen intake and bone density in Asian
populations(6,7); however, studies in Caucasian populations
are limited due to the lower habitual intake of phyto-oestrogens.
In the Shanghai Women’s Health study of 75 000 postmeno-
pausal women, the median intake of soya isoflavones (genistein
and daidzein) was 38 mg/d, and there was a clear association
between soya food consumption and a reduced risk for
fractures(6). In contrast, the median intake of soya isoflavones
in Caucasian women in the Study of Women’s Health Across
the Nation (SWAN) was 0·04 mg/d, while in the same study, the
intake among Chinese (5·3 mg/d) and Japanese (18·9 mg/d)
women was much higher(7).
We investigated the association between dietary phyto-
oestrogens and bone density in 2580 women and 4973 men
in the European Prospective Investigation into Cancer
(EPIC)-Norfolk cohort(8). In addition to soya isoflavones used
in most observational studies conducted thus far, we have
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also included lignans, enterolignans including equol and cou-
mestrol in our analysis. To our knowledge, this is the largest
observational study of the association between phyto-oestro-
gens and bone health conducted in a European population.
Methods
Study population
Between 1993 and 1997, approximately 25 000 healthy men
and women aged between 40 and 75 years were recruited
for the EPIC-Norfolk study from general practitioners’ data-
bases(8). Health and lifestyle, including data on smoking, alco-
hol consumption, social class, family medical history, physical
activity and reproductive history, were assessed by a question-
naire. Postmenopausal status was defined as at least twelve
consecutive months of amenorrhoea. Height and weight
measurements were collected following a standardised proto-
col as part of a health check conducted by research nurses(8).
Diet was assessed by a prospective 7 d diet diary at baseline.
Between 1998 and 2000, men and women then aged 42–82
years were invited to attend a second visit, where quantitative
ultrasound measurements of the calcaneum were conducted
by trained research nurses, according to standardised proto-
cols (n 10 444)(9–11). Men (n 4973) and postmenopausal
women who were not on hormone replacement therapy
(n 2897) were eligible for the present study. The study
was approved by the Norwich District Health Authority
Ethics Committee, and all participants gave signed informed
consent.
Analytical methods
Diet was assessed at baseline with a 7 d diary using the in-
house dietary assessment software DINER (Data into Nutrients
for Epidemiological Research) to calculate average daily nutri-
ent intakes(12). Dietary phyto-oestrogens were determined
using the food composition database for foods commonly
consumed in the UK(13–16). More than 500 different foods
were analysed by liquid chromatography–MS using 13C-
labelled internal standards(13–17); the limit of detection of
this method was 1·5 g/100 g dry weight (intra-batch CV was
between 3 and 14 %; inter-batch CV was between 1 and
6 %). These data were used to calculate the phyto-oestrogens
content of 10 708 foods in DINER.
At the first follow-up visit (1998–2000), quantitative ultra-
sound was used to measure broadband ultrasound attenuation
(BUA, dB/MHz) of the calcaneum. Using the CUBAClinical
machine (McCue Ultrasonics, Winchester, UK), BUA was
measured at least twice on each foot as described pre-
viously(11). A total of five machines were used, and each
Table 1. Descriptive characteristics of the study population at baseline: the European Prospective Investigation into
Cancer-Norfolk study
(Mean values, standard deviations, medians and interquartile ranges)
Women (n 2580) Men (n 4973)










Broadband ultrasound attenuation (dB/MHz)
Mean 64·3 89·7
SD 15·1 17·6
Ca intake (mg/d) 743·4 601·8–910·2 910·4 743·8–1096·2
Nutrient intake (mg/d)
Total phyto-oestrogens 875·7 704·8–1117·2 1212·0 954·0–1557·9
Total isoflavones 619·8 458·1–836·2 875·5 643·5–1198·9
Biochanin A 16·6 12·9–21·7 22·6 17·1–29·9
Daidzein 204·6 149·5–277·8 289·4 209·9–401·1
Formononetin 2·3 1·8–3·0 3·4 2·5–4·9
Genistein 351·6 255·1–480·2 497·0 359·9–684·4
Glycitein 40·9 30·9–52·7 57·8 43·7–74·8
Total lignans 230·0 183·5–291·5 287·1 220·9–372·5
Matairesinol 35·0 27·2–44·0 41·9 32·2–53·6
Secoisolariciresinol 193·7 151·3–249·9 242·7 182·9–320·8
Coumestrol 4·7 3·2–7·2 5·7 3·9–8·6
Total enterolignans and equol 15·6 11·6–20·8 18·1 13·0–23·8
Enterodiol 0·0 0·0–0·1 0·0 0·0–0·1
Enterolactone 11·8 8·7–15·8 13·5 9·9–17·9
Equol 3·8 2·8–5·0 4·4 3·2–5·8

















Table 2. Regression analysis of calcaneal broadband ultrasound attenuation (dB/MHz) and phyto-oestrogen intake (log transformed): the European Prospective Investigation into Cancer-Norfolk
study
(b-Coefficients and 95 % confidence intervals)
Women (n 2580) Men (n 4973)
Multivariable model* Multivariable model þ Ca Multivariable model* Multivariable model þ Ca
b 95 % CI P b 95 % CI P b 95 % CI P b 95 % CI P
Total phyto-oestrogens 0·334 20·707, 1·375 0·530 0·445 20·596, 1·487 0·402 0·208 20·786, 1·203 0·682 0·173 20·821, 1·167 0·732
Total isoflavones 0·036 20·795, 0·866 0·933 0·156 20·676, 0·988 0·713 0·198 20·612, 1·008 0·631 0·160 20·650, 0·970 0·698
Biochanin A 0·891 20·443, 2·225 0·190 0·735 20·601, 2·070 0·281 1·199 0·140, 2·257 0·026 1·176 0·118, 2·233 0·029
Formononetin 1·212 20·125, 2·548 0·076 1·156 20·178, 2·491 0·089 0·764 20·191, 1·718 0·117 0·765 20·189, 1·719 0·116
Daidzein 20·018 20·822, 0·786 0·965 0·093 20·712, 0·898 0·821 0·270 20·515, 1·055 0·500 0·218 20·566, 1·003 0·586
Genistein 0·016 20·767, 0·800 0·967 0·134 20·651, 0·919 0·737 0·191 20·572, 0·953 0·624 0·156 20·605, 0·918 0·687
Glycitein 20·064 21·089, 0·961 0·903 0·085 20·943, 1·113 0·871 20·433 21·462, 0·596 0·409 20·432 21·460, 0·596 0·410
Coumestrol 0·029 20·825, 0·883 0·947 20·103 20·959, 0·753 0·814 0·675 20·147, 1·497 0·107 0·627 20·195, 1·448 0·135
Lignans 1·062 20·381, 2·505 0·149 0·994 20·447, 2·436 0·176 0·478 20·735, 1·692 0·439 0·568 20·646, 1·781 0·359
Matairesinol 20·300 21·667, 1·067 0·667 20·360 21·725, 1·005 0·605 20·719 21·908, 0·469 0·235 20·710 21·897, 0·478 0·241
Secoisolariciresinol 1·085 20·272, 2·441 0·117 1·023 20·331, 2·378 0·139 0·626 20·510, 1·761 0·280 0·711 20·425, 1·847 0·220
Total enterolignans and equol 1·505 0·346, 2·664 0·011 20·033 22·009, 1·944 0·974 0·160 20·393, 0·713 0·570 20·293 20·914, 0·327 0·354
Enterolactone 1·424 0·311, 2·537 0·012 20·030 21·879, 1·819 0·975 0·195 20·355, 0·745 0·487 20·257 20·876, 0·363 0·417
Equol 1·523 0·367, 2·680 0·010 0·199 21·622, 2·021 0·830 0·126 20·444, 0·696 0·665 20·341 20·978, 0·296 0·294
Ca† 3·161 1·048, 5·274 0·003 – – – 3·544 1·517, 5·572 0·001 – – –
* Adjusted for age (years), BMI (kg/m2) and energy intake (MJ/d).
† Log transformed.
Table 3. Regression analysis of calcaneal broadband ultrasound attenuation (dB/MHz) and phyto-oestrogen intake (log transformed), stratified by calcium intake*: the European Prospective Investi-
gation into Cancer-Norfolk study
(b-Coefficients and 95 % confidence intervals)
Women Men
Low intake† High intake‡ Low intake§ High intakek
b 95 % CI P b 95 % CI P b 95 % CI P b 95 % CI P
Total phyto-oestrogens 1·829 20·330, 3·987 0·097 20·274 22·647, 2·100 0·821 0·121 21·978, 2·220 0·910 0·089 22·044, 2·223 0·935
Total isoflavones 1·441 20·269, 3·151 0·098 20·475 22·375, 1·424 0·623 0·076 21·623, 1·774 0·930 0·041 21·713, 1·796 0·963
Biochanin A 0·568 22·201, 3·338 0·687 1·252 21·948, 4·451 0·442 1·131 20·928, 3·190 0·281 20·331 22·717, 2·055 0·786
Formononetin 1·082 21·602, 3·766 0·429 20·947 24·073, 2·180 0·552 20·235 22·094, 1·624 0·804 0·268 21·982, 2·519 0·815
Daidzein 1·388 20·260, 3·036 0·099 20·486 22·325, 1·354 0·604 0·061 21·563, 1·686 0·941 0·150 21·551, 1·851 0·863
Genistein 1·358 20·263, 2·979 0·100 20·454 22·231, 1·324 0·616 0·178 21·420, 1·775 0·827 0·009 21·640, 1·658 0·991
Glycitein 1·930 20·125, 3·985 0·066 21·138 23·520, 1·244 0·348 0·286 21·786, 2·357 0·787 20·909 23·147, 1·329 0·426
Coumestrol 20·641 22·495, 1·213 0·497 0·580 21·427, 2·587 0·570 0·970 20·681, 2·620 0·249 0·851 20·998, 2·701 0·366
Total lignans 2·491 20·875, 5·857 0·147 0·209 22·991, 3·409 0·898 0·046 22·373, 2·465 0·970 0·024 22·681, 2·729 0·986
Matairesinol 0·505 22·513, 3·523 0·743 1·522 21·766, 4·809 0·364 0·594 21·776, 2·964 0·623 20·419 23·101, 2·262 0·759
Secoisolariciresinol 2·492 20·665, 5·648 0·122 20·081 23·054, 2·892 0·957 0·023 22·244, 2·290 0·984 0·190 22·334, 2·713 0·883
* Adjusted for age (years), BMI (kg/m2) and energy intake (MJ/d).
† Bottom quintile (198–570 mg/d).
‡ Top quintile (958–2363 mg/d).
§ Bottom quintile (161–699 mg/d).
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Table 4. Age, energy intake, broadband ultrasound attenuation (BUA) and phyto-oestrogen intake in the top and bottom quintiles of calcuim intake in the European Prospective Investigation into
Cancer-Norfolk study
(Medians and interquartile ranges)
Women Men
Low intake* High intake† Low intake‡ High intake§
Median Interquartile range Median Interquartile range Pk Median Interquartile range Median Interquartile range Pk
Ca (mg/d) 487 422–532 1076 1008–1182 ,0·01 605 531–660 1311 1217–1443 ,0·01
Age (years) 67·0 62·0–71·0 65·0 61·0–70·0 ,0·05 63·0 57·0–69·0 60·0 53·0–66·0 ,0·01
BMI (kg/m2) 25·8 23·6–29·1 25·5 23·3–28·0 ,0·05 26·6 24·5–28·6 25·8 24·1–27·9 ,0·01
Energy intake (MJ/d) 5·6 4·9–6·4 8·3 7·5–9·2 ,0·01 7·5 6·5–8·6 11·0 9·8–12·4 ,0·01
BUA (dB/MHz) 61·8 51·9–74·2 64·6 55·1–73·7 ns 86·9 76·0–101·3 88·7 78·4–100·4 ns
Intake (mg/d)
Total phyto-oestrogens 780·5 615·3–950·7 846·7 694·8–1085·9 ,0·01 1002·8 782·3–1301·3 1386·3 1107·6–1802·4 ,0·01
Isoflavones 563·9 400·6–728·2 606·4 459·6–833·7 ,0·01 704·2 516·2–984·3 1029·1 755·0–1403·6 ,0·01
Biochanin A 13·2 10·1–16·8 15·9 12·3–20·4 ,0·01 17·8 13·3–24·2 26·7 20·7–34·5 ,0·01
Formononetin 1·9 1·4–2·5 2·2 1·7–2·9 ,0·01 2·7 1·9–3·9 4·0 3·1–5·5 ,0·01
Daidzein 184·1 131·2–242·9 202·6 150·6–275·1 ,0·01 228·1 166·6–326·2 339·5 251·9–468·5 ,0·01
Genistein 319·9 223·3–415·5 343·6 254·8–473·2 ,0·01 398·9 287·7–558·9 579·3 420·5–796·3 ,0·01
Glycitein 36·3 26·2–47·1 40·0 31·0–51·5 ,0·01 48·3 36·0–63·9 66·2 50·8–84·2 ,0·01
Coumestrol 4·0 2·5–6·2 4·3 3·0–6·5 ,0·01 4·4 3·1–7·3 6·6 4·8–9·7 ,0·01
Lignans 199·3 157·3–262·1 223·4 176·3–284·9 ,0·01 249·4 185·5–335·7 315·2 247·9–399·2 ,0·01
Matairesinol 30·1 22·0–39·1 33·9 26·7–42·2 ,0·01 36·6 26·9–48·1 46·3 35·7–58·4 ,0·01
Secoisolariciresinol 170·1 130·4–221·6 187·8 145·1–244·8 ,0·01 215·2 155·5–292·0 265·9 205·0–346·5 ,0·01
* Bottom quintile (198–570 mg/d).
† Top quintile (958–2363 mg/d).
‡ Bottom quintile (161–699 mg/d).
§ Top quintile (1152–3251 mg/d).
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machine was calibrated daily with their physical phantom
and monthly with a roving phantom and on one operator’s
calcaneum. As there was no effect of adjustments for tempera-
ture or machine, the data in the present study are presented
unadjusted for temperature or machine(18).
Data analysis
Descriptive characteristics of the study population were
summarised using means and standard deviations for normally
distributed continuous variables, frequency and percentages
for categorical variables and medians (interquartile ranges)
for non-normally distributed continuous variables. The
bottom quintile of Ca intake was defined as ‘low’ intake
(women 198–570 mg/d and men 161–699 mg/d); the top
quintile as ‘high’ intake (women 958–2363 mg/d and men
1152–3251 mg/d).
Associations between BUA and log-transformed phyto-
oestrogen intake were investigated using linear regression
models, including age, BMI and total energy intake; potential
confounders (age, BMI, energy intake and physical activity)
were evaluated through comparison of models with and with-
out the variable under examination, and were retained in the
final model if their inclusion resulted in changes to the
regression coefficient for total phyto-oestrogens intake of
more than 10 %. For the regression analysis, dietary intake
was log transformed. Dietary Ca and phyto-oestrogens were
correlated using Spearman’s rank correlation. Interactions
between phyto-oestrogen intake and Ca intake were investi-
gated by including an interaction term in the regression
model. All analyses were conducted with STATA (version 10
for UNIX; Stata Corporation, College Station, TX, USA).
Results
BUA, anthropometric and dietary data were available for 4973
men and 2580 women who were postmenopausal and never
on hormone replacement therapy. Table 1 shows demo-
graphic, anthropometric and dietary information of the study
population. Median intake of phyto-oestrogens was lower in
women (0·9 mg/d) than among men (1·2mg/d). Among both
sexes, the most common types of phyto-oestrogen were
the isoflavones daidzein (205mg/d in women and 289mg/d
in men) and genistein (352mg/d in women and 497mg/d in
men), and the lignan secoisolariciresinol (194mg/d in
women and 243mg/d in men), with lower intakes in women
than in men.
The results of the regression analyses are summarised in
Table 2. In postmenopausal women, regression analyses
with age, BMI and energy intake as covariables showed no
significant association for total phyto-oestrogens, total isofla-
vones, coumestrol or lignans. Only formononetin showed a
borderline significant positive association (b ¼ 1·2; P,0·1),
which remained significant when including dietary Ca in the
model (b ¼ 1·2; P,0·1). However, there was a significant
association for total enterolignans and equol (b ¼ 1·5;
P,0·05), enterolactone (b ¼ 1·4; P,0·05) and equol
(b ¼ 1·5; P,0·05). When including dietary Ca as a covariable,
these associations became non-significant. In men, only
biochanin A was positively associated with BUA (b ¼ 1·2;
P,0·05), and this association remained significant when
including dietary Ca in the model (b ¼ 1·2; P,0·02). Dietary
Ca was significantly associated with BUA in women
(b ¼ 3·2; P,0·005) and men (b ¼ 3·5; P,0·005), and it was
significantly correlated with enterolactone and equol intake
(Spearman’s r 0·88, P,0·001 in men; 0·90, P,0·001 in
women).
Formal tests for interaction between Ca and phyto-oestrogen
intake were conducted but showed no significant result.
Following stratification of data by Ca intake, a borderline sig-
nificant association was found in women between BUA and
the intake of total phyto-oestrogens (b ¼ 1·8; P,0·1) and iso-
flavones (b ¼ 1·4; P,0·1), in particular the soya isoflavones
daidzein (b ¼ 1·4; P,0·1), genistein (b ¼ 1·4; P,0·1) and
glycitein (b ¼ 1·9; P,0·1) in the lowest quintile of Ca intake
(Table 3). No significant association was found in the highest
quintile and in men. BUA was not significantly different
between the highest and lowest quintiles of Ca intake
(Table 4); however, participants in the lowest quintile were
significantly older and had a higher BMI, but consumed
a lower amount of phyto-oestrogens.
Discussion
The present investigation of phyto-oestrogen intake and bone
density is the largest prospective study in a Western popu-
lation undertaken so far. The EPIC-Norfolk cohort was well
positioned to investigate the associations between dietary
phyto-oestrogens and bone density in a Western population
and to improve the observational data available. Whereas
most studies conducted previously have investigated only
the effect of the so-called soya isoflavones daidzein and
genistein(19), the present study also included other isoflavones
and other types of phyto-oestrogens such as lignans, coumes-
trol, enterolignans and equol using data from a newly devel-
oped food composition database(20). A further strength of
the present study is the use of 7 d food diaries. However, a
limitation of the study is that only information for two types
of lignans, matairesinol and secoisolariciresinol, are available.
A further limitation of the present study, as with other studies
relying on dietary data to assess exposure to phyto-oestro-
gens, is that inter-individual differences in metabolism, in
particular the conversion of phyto-oestrogens to equol,
O-desmethylangolensin and enterolignans by the intestinal
microflora, cannot be accounted for. In the present study,
we used BUA instead of dual-energy X-ray absorptiometry
(DXA); quantitative ultrasound or BUA has been identified
as a reliable and accurate tool for the assessment of osteo-
porosis and fracture risk. A recent comparison has shown
that quantitative ultrasound is at least as reliable as DXA for
the prediction of fractures in the elderly(21,22).
Compared with the dietary intake of genistein and daidzein
in other observational studies, the median intake in women
of the EPIC-Norfolk cohort was higher than in European
women in the SWAN study (0·6 v. 0·04 mg/d) and cohorts in
The Netherlands (0·4 mg/d(23)) and Canada (0·2 mg/d(24)),

















but lower than in a Californian cohort (1·7 mg/d(25)) and much
lower than in Japanese (7·2 mg/d) or Chinese (3·5 mg/d) par-
ticipants of the SWAN study(7) or in the Shanghai Women’s
Health Study (38·0 mg/d(6)).
Significant or borderline significant positive associations
between dietary phyto-oestrogens and bone density measured
as BUA were only found for the non-soya isoflavones formo-
nonetin in women and biochanin A in men; high amounts of
these compounds are found, for example, in chick peas(16).
Formononetin and biochanin A are both 30-methylated isofla-
vonoids, which differ only in the presence of an hydroxyl
group in the 50-position; however, it is not possible to investi-
gate whether this structural difference explains the observed
associations with the data available.
There was no significant association between any lignan
and bone density. Although the coumestan coumestrol was
the first phyto-oestrogen for which animal studies have
suggested a protective effect on bones(26), no significant
effect was found in the present study.
Strong significant associations were observed for the so-
called ‘mammalian phyto-oestrogens’, enterolactone and
equol, in postmenopausal women, but not in men. These
compounds are formed from lignans and daidzein, respect-
ively, by the gastrointestinal microflora(27). So far, it has not
been possible to investigate the associations between these
compounds and bone density directly, as insufficient infor-
mation on the dietary content of these compounds was
available.
Dietary Ca is an important contributor to bone health(28,29)
and positively associated with bone density. We have there-
fore investigated the effect of dietary Ca on the associations
observed. Whereas no significant effect was observed for
phyto-oestrogens of plant origin, the associations between
BUA and enterolignans and equol in postmenopausal
women were attenuated and became non-significant. The
main sources of enterolignans and equol in the diet of partici-
pants of the EPIC-Norfolk study are cheese and other dairy
products(13), which are also a main source of Ca, and the
strong correlation between these compounds and dietary Ca
is a possible explanation. The high correlation limits our abil-
ity to identify which dietary factor exerted greater influence,
and it is possible that enterolignan and equol intake does
affect bone density but is attenuated on adjustment for dietary
Ca as a result of collinearity.
We have further investigated the effect of Ca by stratifying
the cohort by Ca intake: in the lowest quintile of Ca intake
(less than 570 mg/d) in postmenopausal women, total phyto-
oestrogens, total isoflavones and soya isoflavones were all
positively associated with BUA, although the association was
only borderline significant; the association was non-significant
for higher dietary Ca intake; no significant associations were
found in men. The differences between postmenopausal
women in the top and bottom quintiles of Ca intake do not
provide an obvious explanation for the observed associations.
These results confirm observations from previous studies,
which have shown that the beneficial effect of soya on bone
density is stronger in subjects with lower dietary Ca
intake(30–32). The mean Ca intake in cohort studies, which
showed a positive association between soya intake and
bone health, was below 650 mg/d in the Shanghai Women’s
Health Study(6) and the Chinese and Japanese participants of
the SWAN study(7). These data suggest that with low Ca
intake, soya intake can affect bone density; the strong associ-
ation in populations with high habitual soya consumption,
and the weak association in this cohort, also suggest a
dose–response effect. However, there are still insufficient
data available to explain this association.
The results in postmenopausal women clearly suggest an
interaction between dietary Ca, soya and bone density. Con-
versely, the results for men do not suggest such an interaction:
enterolignans and equol were not associated with BUA, and
no significant associations were observed after stratification
for Ca intake.
The magnitude of the relationship observed (difference of
adjusted means between the top and bottom quintiles of
intake) was 1·5 dB/MHz of BUA in men, and between
1·2 dB/MHz (for formononetin) and 2·1 dB/MHz (total phyto-
oestrogens in the lowest quintile of Ca intake) in postmeno-
pausal women. Although this estimate would be attenuated
due to the random measurement error in dietary intake, it is
of interest in terms of the physiological relationship between
dietary phyto-oestrogen intake and BUA. A reduction of
1 SD of BUA (20 dB/MHz) is associated with about doubling
in the risk of fracture(10), so 2 units might be associated with
a 10 % difference in fracture risk.
In conclusion, our data indicate an independent association
between the non-soya isoflavones formononetin and biocha-
nin A and bone density in postmenopausal women and
men, respectively. Positive associations observed for entero-
lignans and equol in postmenopausal women became non-
significant following adjustment for Ca intake, and the likely
explanation for most compounds is that these compounds
act as a surrogate marker for Ca. In postmenopausal women
with low habitual Ca intake, soya isoflavones were borderline
significantly associated with increased BUA in postmenopau-
sal women, confirming reports from previous studies. Our
results therefore suggest that non-soya isoflavones are
associated with bone density independently of Ca, whereas
the association with soya or soya isoflavones is affected by
dietary Ca.
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